Furthermore, EGCG is a potent and selective inhibitor of DYRK1A activity, a kinase encoded by the Hsa21 gene DYRK1A, and thus overexpressed in DS, that participates in numerous molecular pathways related to some of the altered phenotypes of this syndrome. This evidence concerns the gene DYRK1A and Dravet syndrome.